Product Description
AM-411 is an intravenously administered nanoparticle based on the OligoPhore™ platform targeting p65, one of the main transcriptional regulators of the NF-kB pathway and a key checkpoint in RA inflammation. AM-411 has been designed to reduce local inflammation without affecting the NF-kappaB pathway elsewhere and is less likely to generate resistance because it reduces synthesis of p65 rather than blocking the protein. An IND filing is planned for 2024. (Sourced from: https://altamiratherapeutics.com/rna-programs)
Mechanisms of Action: NFkB-p65 Reducer
Novel Mechanism: Yes
Modality: N/A
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Altamira Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Arthritis, Rheumatoid
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|